Precision-Designed Parasiticides

Crafting next generation of small molecule anti-parasitic drugs by harnessing comparative structural data.

Our Vision

At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of Parabulins™. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions.

Targeting the Molecular Infrastructure of Parasites

At ASTRA Therapeutics, we see microtubules as both the foundation of life and a key weakness in parasites. These dynamic structures drive Parasite invasion, replication, and survival— making them a powerful drug target. By disrupting parasite microtubules with precision, we're pioneering unparalleled strategies to combat parasitic diseases.

Our Challenge

Unlike bacterial or viral pathogens, parasites share key molecular features with their hosts, making selective targeting a major challenge. This issue, compounded by rising drug resistance, poses a serious threat to global health and food security. With our revolutionary ParaX™ platform, we are changing the game—designing highly selective treatments that target parasite microtubules while protecting host cells.

Revolutionising the Fight

At ASTRA Therapeutics, we have mastered the art of precision. Our proprietary technology has led to the discovery of Parabulins™- tubulin-binding inhibitors that selectively target parasite microtubules, leaving host cells unharmed. Our Parabulins™ are designed to tackle multiple protozoan and worm parasites. These innovative treatments are not only highly effective but also safer for hosts, setting a new standard in parasite control.

Explore how Parabulins™ are changing the game in parasitic disease treatment.

Join us in shaping a healthier future at ASTRA Therapeutics.